Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
The Chinese medical team’s Revolutionary CAR-T Therapy: Long-lasting asthma relief with a single injection
### 🚀 The Chinese medical team’s Revolutionary CAR-T Therapy: Long-lasting asthma relief with a single injection.!
asthma
📢 Exciting news from the world of medical science! The team led by Professor Peng Min at Tsinghua University has made a groundbreaking advancement in CAR-T cell therapy. Imagine a world where chronic diseases like allergic asthma can be managed with just a single injection. This could soon be a reality!
🌬 **Asthma: A Global Challenge**
Asthma is one of the most common respiratory diseases, affecting over 300 million people worldwide and causing approximately 250,000 deaths annually. Despite the availability of treatments, many patients require lifelong medication, which can be costly and burdensome.
💡 **The Breakthrough Study**
On May 27, 2024, the team published their findings in *Nature Immunology*. Their paper, titled *A single infusion of engineered long-lived and multifunctional T cells confers durable remission of asthma in mice*, introduces a novel CAR-T cell named 5TIF4. This engineered cell targets the factors that trigger allergic reactions. Remarkably, just one injection of 5TIF4 cells was enough to suppress signs and symptoms of allergic asthma in mice for an extended period.
🧬 **How Does It Work?**
Traditional therapies for chronic diseases often require repeated or lifelong administration. However, the 5TIF4 cells are designed to be long-lived and multifunctional. They can neutralize eosinophils (cells involved in allergic reactions) and block key pathways (IL-4 and IL-13 signaling) that drive asthma. This innovative approach not only targets the symptoms but also addresses the underlying causes of the disease.
🚧 **Challenges and Solutions**
While CAR-T therapy has revolutionized cancer treatment, applying it to non-cancerous diseases presents unique challenges:
-
**Targeting Non-Cancer Tissues**: Unlike tumors, affected organs like lungs in chronic diseases cannot be eliminated.
-
**Longevity of Therapy**: Chronic diseases are lifelong, necessitating long-lasting therapeutic cells.
-
**Safety**: Current CAR-T treatments often involve invasive procedures like chemotherapy, which are not suitable for chronic conditions.
Peng Min’s team overcame these hurdles by engineering CAR-T cells that do not require pre-treatment and can persist in the body, providing continuous protection against asthma.
💭 **Future Prospects**
The implications of this research are profound. If these results can be replicated in humans, we might see a new era where a single injection offers long-term relief from asthma. Moreover, the same principles could potentially be adapted to treat other diseases involving eosinophils and type 2 cytokines, such as allergies, atopic dermatitis, and eosinophilic esophagitis.
📰 *Nature Immunology* also highlighted this study in an article titled *CAR T cells put the brakes on asthma*, emphasizing the expanding scope of CAR-T therapy beyond cancer treatment.
🌟 **Conclusion**
This pioneering research by Tsinghua University marks a significant milestone in the fight against chronic diseases. With further clinical trials, we could be on the brink of a revolution in how we treat asthma and possibly other chronic conditions. Stay tuned for more updates on this exciting journey towards better health and wellness!
📸 Don’t forget to follow for more groundbreaking health news and updates!
🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com
#MedicalBreakthrough #CARTCellTherapy #AsthmaRelief #TsinghuaUniversity #HealthRevolution
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
China’s First CAR-T Trial: “Pay-for-Performance” Introduced!
China’s First CAR-T Trial: “Pay-for-Performance” Introduced! 
CAR-T
China has taken a groundbreaking step towards pay-for-performance! Fosun Kite announces an exciting initiative: the ¥1.2 million(RMB) #CARTcell therapy will now be paid based on its effectiveness! 
NO CR – Refund
This means that eligible patients using Fosun Kite’s #CARTtherapy, #Axicabtagene Ciloleucel, will undergo effectiveness assessment three months after drug purchase and infusion. If complete remission (CR) is not achieved, patients will receive a refund of up to ¥600,000(RMB)! 
This innovative payment model
is not only China’s first for lymphoma drugs but also the country’s first for bio-innovative drugs! 
is an immunotherapy method that involves genetically modifying a patient’s T cells outside the body to recognize specific tumor targets before reinfusing them to precisely combat #tumors. Currently, five products, including Fosun Kite’s #AxicabtageneCiloleucel, have been approved domestically. 
As a form of immunotherapy, CAR-T cell therapy works by collecting a patient’s T cells and genetically modifying them outside the body to recognize specific tumor targets. These modified T cells are then reintroduced into the patient, enabling precise targeting and attacking of tumors. Currently, there are five approved products domestically, including Axicabtagene Ciloleucel from Fosun Kite, Relmacabtagene Autoleucel from JW Therapeutics, Equecabtagene Autoleucel from IASO Bio, Inaticabtagene Autoleucel from Juventas, and Zevorcabtagene autoleucel from CARsgen.
